

## Cellular & Molecular Medicine: Open Access

ISSN: 2573-5365 | Google Scholar | CIF: 5.62

**Eve Brown\***

Managing Editor, Cellular & Molecular  
Medicine, 483, Green Lanes, London

**Received:** February 17, 2021, **Accepted:** March 21, 2021, **Published:** March 29, 2021

**Cellular & Molecular Medicine: Open access** is a peer reviewed, open access journal that encompasses all fundamental and molecular aspects of medicine. The Journal publishes current and comprehensive reviews, original research articles, short communications/letters, drug clinical trial studies and short reports.

Areas within the scope include, but are not limited to: Molecular Clinical Trials, Methods in Molecular Medicine, Nuclear Molecular Medicine, Pathology & Molecular Medicine, Cellular medicine, Molecular medicine, Genetic Medicine, Gene Therapy, Medical Biology, Nuclear Medicine, Metabolomics, Stem cell medicine, Tissue engineering, Cellular and Molecular Basis of Disease, Genetic testing, Proteomics, Bioinformatics, Computer applications in human biology, Stem cells and tissue engineering, Medical biotechnology, Nano medicine, Cellular processes related to growth, death and survival, Clinical biochemistry, Molecular & cellular immunology.

The journal runs on Bi-monthly issue release with a release every January, March, May, July, September, and November. The journal has successfully completed 6 volumes and is currently running its 7<sup>th</sup> volume. The journal is indexed in Google Scholar, China


### Table of content

<b><i>Spinal Cord Injury Induced Hyperalgesia is Associated with Increased Levels of Let-7 Family of MicroRNAs</i></b>	
Author(s)	Carlene Callahan, Michelle Yanik, Dorothy Dobbins, Kori LB (USA)
<b><i>Selective HDAC6 Inhibition Corrects Aberrant B Cell Development in the Bone Marrow of NZB/W F1 Mice</i></b>	
Author(s)	Miranda DV, Xin ML, Song L, Alexander MG, Adrian C (USA)
<b><i>Natriuretic Peptides, Heart, Cancer and the Cardio-Oncology</i></b>	
Author(s)	Jose LA, and Francisco JA (Spain)

**\*Corresponding authors:** Eve Brown

Managing Editor, Cellular & Molecular  
Medicine, 483, Green Lanes, London

**Whatsapp:** +44-7723-59-8358

 cellularmedicine@imedpub.org

**Citation:** Brown E (2021) Cellular & Molecular Medicine: Open Access ISSN: 2573-5365 | Google Scholar | CIF: 5.62. Cell Mol Med. Vol. 7 No. 2: 7.

National Knowledge Infrastructure (CNKI), Cosmos IF, Geneva foundation for medical education and research, and Secret Search Engine Labs.

**Submission Portal:** Online Submission System or send as an attachment to: cellmolmed@journalres.com your response is highly appreciated. We are always ready for providing further information and assistance as and when required.

**Regards,**

Eve Brown

Managing Editor

Cellular & Molecular Medicine

483, Green Lanes, London

Whatsapp: +44-7723-59-8358

Email: cellularmedicine@imedpub.org

## References

- 1 Mandal M, Breaker RR (2004). Gene regulation by riboswitches. *Nat Rev Mol Cell Biol* 6: 461-463.
- 2 Ellington AD, Szostak JW (1990). *In vitro* selection of RNA molecules that bind specific ligands. *Nature* 346: 818-822.
- 3 Tuerk C, Gold L (1990). Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. *Science* 249: 606-610.
- 4 Gold L (1996). The SELEX process: A surprising source of therapeutic and diagnostic compounds. *Harvey Lect* 91: 47-67.
- 5 Famulok M, Mayer G, Blind M (2000). Nucleic acid aptamers-from selection *in vitro* to applications *in vivo*. *Acc Chem Res* 33: 691-699.
- 6 Kurreck J (2003). Antisense technologies. Improvement through novel chemical modifications. *Eur J Biochem* 27: 1628-1644.
- 7 Conrad R, Keranen LM, Ellington AD (1994). Newton, A.C. Isozyme-specific inhibition of protein kinase C by RNA aptamers. *J Biol Chem* 269: 32061-32064.
- 8 Shoji A, Kuwahara M, Ozaki H, Sawai H (2007). Modified DNA aptamer that binds the (R)-isomer of a thalidomide derivative with high enantioselectivity. *J Am Chem Soc* 129: 1466-1464.
- 9 Ruta J, Ravelet C, Baussanne I, Decout JL, Peyrin E (2007). Aptamer-based enantioselective competitive binding assay for the trace enantiomer detection. *Anal Chem* 79: 4716-4719.
- 10 Farokhzad OC, Cheng J, Teply BA, Sherifi I (2006). Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy *in vivo*. *Proc Natl Acad Sci* 103: 6316-6320.